Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Assets (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Non-Current Assets for 4 consecutive years, with $107.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 41.4% to $107.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $536.7 million, a 26.28% decrease, with the full-year FY2024 number at $159.2 million, down 13.35% from a year prior.
  • Non-Current Assets was $107.0 million for Q3 2025 at Century Therapeutics, down from $124.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $255.9 million in Q2 2023 to a low of $107.0 million in Q3 2025.
  • A 4-year average of $173.0 million and a median of $166.8 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 71.97% in 2023, then plummeted 41.53% in 2025.
  • Century Therapeutics' Non-Current Assets stood at $166.8 million in 2022, then rose by 10.11% to $183.7 million in 2023, then dropped by 13.35% to $159.2 million in 2024, then plummeted by 32.77% to $107.0 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Non-Current Assets are $107.0 million (Q3 2025), $124.5 million (Q2 2025), and $146.0 million (Q1 2025).